Literature DB >> 6997673

Legionnaires' disease: report of sixty-five nosocomially acquired cases of review of the literature.

B D Kirby, K M Snyder, R D Meyer, S M Finegold.   

Abstract

Sixty-five cases of nosocomially acquired Legionnaires' disease are reported and the world literature is reviewed. The etiologic agent, Legionnella pneumophila, has been isolated from several environmental sources at outbreak sites. Legionnaires' disease appears to be acquired by inhalation and is primarily manifested by severe, potentially fatal, pneumonia. Characteristic clinical disease consists of high fever with relative bradycardia, dry cough, chills, diarrhea, and pleuritic pain. Although no single feature is pathognomonic, the clinical presentation is usually sufficiently characteristic to suggest the diagnosis. The diagnosis of Legionnaires' disease during acute illness may be established by culture of Legionella pneumophila, or by demonstration of the bacterium using special stains. However, in most instances, the physician must make a presumptive diagnosis based on the clinical presentation in order to institute appropriate antimicrobial therapy. Retrospective confirmation of the diagnosis may be made by serologic studies in most instances. Erythromycin is, at this time, the drug of choice for the treatment of Legionnaires' disease. A prompt salutory response following institution of erythromycin therapy is typical.

Entities:  

Mesh:

Year:  1980        PMID: 6997673

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  58 in total

1.  A pseudo community outbreak of legionnaires' disease on Merseyside; implications for investigation of suspected clusters.

Authors:  C M Regan; Q Syed; K Mutton; B Wiratunga
Journal:  J Epidemiol Community Health       Date:  2000-10       Impact factor: 3.710

Review 2.  Nosocomial pneumonia: epidemiology and infection control.

Authors:  D E Craven; K A Steger; L M Barat; R A Duncan
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

3.  Radiographic appearance of nosocomial legionnaires' disease after erythromycin treatment.

Authors:  C Domingo; J Roig; F Planas; J Bechini; M Tenesa; J Morera
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

4.  Legionnaires' disease in the immunocompromised host: usefulness of Gram's stain.

Authors:  D Baptiste-Desruisseaux; R Duperval; J A Marcoux
Journal:  Can Med Assoc J       Date:  1985-07-15       Impact factor: 8.262

5.  Microscopic polyarteritis: a forgotten aetiology of haemoptysis and rapidly progressive glomerulonephritis.

Authors:  S Zashin; R Fattor; D Fortin
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

6.  Legionella micdadei lung abscess in a patient with HIV-associated nephropathy.

Authors:  C Nzerue; A Gowda
Journal:  J Natl Med Assoc       Date:  2001-06       Impact factor: 1.798

7.  Effect of immunosuppressive therapy on the clinical presentation of legionellosis.

Authors:  K Skogberg; P Ruutu; I Koivula; H Jousimies-Somer; V Valtonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

8.  Potable water and nosocomial Legionnaires' disease--check water from all rooms in which patient has stayed.

Authors:  T J Marrie; W Johnson; S Tyler; G Bezanson; D Haldane; S Burbridge; J Joly
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

9.  Characterization of a lipoprotein common to Legionella species as a urinary broad-spectrum antigen for diagnosis of Legionnaires' disease.

Authors:  Min Ja Kim; Jang Wook Sohn; Dae Won Park; Seung Chul Park; Byung Chul Chun
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.